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ABSTRACT 
 
     Delivery of exogenous materials such as nucleic acids, peptides, proteins, and drugs into cells is an 
important strategy in modern cellular and molecular biology. Recently, the development of gene carriers 
for efficient gene transfer into cells has attracted a great attention. Furthermore, lack of effective drug 
delivery is one of the major problems of cancer chemotherapy. Many physical methods have been studied 
to enhance the efficiency of gene and drug delivery. These strategies help to cross the materials from 
membranes including needle injection, photodynamic therapy, jet injection, gene gun, electroporation, 
hydrodynamic injection, laser, magnetofection, and tattooing. The physical systems improve the transfer 
of genes from extracellular to nucleus by creating transient membrane pores using physical forces 
including local or rapid systemic injection, particle impact, electric pulse, ultrasound, and laser 
irradiation. The recent optimization techniques of transdermal patches could improve the transdermal 
drug delivery through the skin. Among different physical carriers, electroporation and gene gun are the 
most potent methods for gene transfection and drug delivery in vivo. However, the researchers have 
focused on enhancing their potency with the structural modifications. Regarding to numerous barriers for 
biomolecules delivery in cells, this review is concentrated on description and optimization of different 
physical delivery systems for gene or drug transfer across membrane. 
Keywords: Non-viral delivery system; Physical carriers; Drug delivery; Gene transfer 
INTRODUCTION 
     Development of an efficient delivery system 
is important for basic research of therapeutic 
materials such as peptides, proteins, DNA, 
siRNA and drugs. The ideal vectors for gene 
delivery would have at least four properties 
including: a) specificity for the targeted cells; b) 
resistance to metabolic degradation and/or attack 
by the immune system; c) safety; and d) an 
ability to express efficiently [1]. Among 
different carriers, non-viral vectors have benefits 
due to simple use, easy production in large-
scale, and lack of specific immune response to 
vector [2]. Non-viral gene delivery system 
depends on chemical (e.g., cationic polymer and 
lipid) or physical (e.g., electroporation and gene 
gun) transfer of the genetic material and thus 
relies on cellular transport systems for uptake 
and expression in the host cell [2, 3]. Physical  
 
 
approaches such as needle injection, 
electroporation, gene gun, and ultrasound have  
been efficiently used to transfer gene into cells 
in vitro and in vivo. These methods utilize a 
physical force that permeates the cell membrane 
and facilitates intracellular gene transfer [4]. 
Figure. 1 shows some major physical delivery 
systems. However, physical techniques for gene 
delivery into cells, with and without adjuvants, 
should be significantly optimized for different 
goals such as local injection, systemic 
administration, and organ specific delivery [2]. 
Recently, a variety of strategies have been 
developed to enhance DNA vaccine efficacy [5]. 
The researchers explained different delivery 
systems that make the epidermal and dermal 
layers of the skin accessible for vaccine 
administration. Depending on the device, the 
desired vaccine can be used either as a liquid 
formulation or as solid vaccine particles 
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instance, tattooing can be applied to deliver 
liquid vaccine formulations into the dermal layer 
of the skin; and/or microneedles are made of 
vaccine-coated solid or biodegradable 
microneedles. Delivery devices using liquid 
vaccine formulations are useful, because 
established vaccine formulations can be used 
without the need for re-formulation. However, 
approaches that deliver vaccines in a solid form 
may also prove to be promising such as the 
ballistic approaches [6]. Regarding to the 
studies, different physical approaches need to be 
optimized for efficient drug and gene delivery in 
targeted cells especially tumor cells e.g., 
injection sites (skin, muscle, systemic-mediated 
delivery …), device properties (pulse, electric 
field …), cell type and animal model. In this 
review, we will briefly discuss and evaluate the 
efficiency of main physical methods for gene 
and drug delivery in vitro and in vivo.  
Targeted gene/ drug delivery 
     Physical methods of gene and/or drug 
transfer must induce reversible alterations in the 
plasma membrane to allow the direct movement 
of the therapeutic materials into cells and 
facilitate access to the inside of the cell [7]. 
However, cell specificity is an important subject 
for the selection of the approaches. Specificity 
can be obtained in two principal ways: a) 
physical targeting which relies on the spatial 
focus of physical methods including ultrasound, 
magnetofection, gene gun, electroporation, 
hypothermia, hydrodynamic delivery, and 
photodynamic therapy. Herein, a directed 
mechanical force, magnetic or electrical field, 
temperature or light can be used for specific 
localization; b) special biological and 
pharmacological characteristics of the target; 
e.g., tumors [7].  
Needle injection 
     The simplest physical method for gene 
delivery is by direct injection of DNA through a 
needle-carrying syringe into tissue. The major 
application of this strategy is DNA vaccination. 
The studies showed the expression of transgene 
after a plasmid DNA injection to skin, cardiac 
muscle, liver, and solid tumor. The disadvantage 
of this procedure is low gene delivery, as well as 
limitation of the transfected cells to the needle 
injection site. Some efforts have been made to 
achieve a high level of transgene expression by 
optimizing plasmid construct [8]. 
Microfabricated needles were developed using 
several materials such as glass, silicon, and 
metal. They can be used to deliver agents 
through the skin, into a blood vessel, or into a 
cell, and can extract fluids by reversing the flow 
direction. In addition, these systems can be 
integrated with microelectrodes to determine the 
cellular response to agents in real time [9]. 
Delivery to the cornea by microinjection into 
different corneal tissue was described in several 
studies [10]. Microinjection to single cells has 
been extensively used for transduction-
challenged cells, production of transgenic 
animal, and in vitro fertilization to transfer 
DNA, RNA interferences (RNAi), sperms, 
proteins, peptides and drugs (Figure.1). The 
advantages of microinjection include the 
accuracy of delivery dosage and timing, high 
efficiency of transduction as well as low 
cytotoxicity. Compared to electroporation, 
microinjection requires low protein amounts. 
This is efficient for transferring recombinant 
proteins and synthesized peptides with high cost. 
In contrast with chemical transfection (e.g., 
liposomes) and viral infection, microinjection of 
the cDNAs into cells is less stressful; therefore, 
it decreases the cell death observed by these 
systems. Furthermore, more than one construct 
can be injected into different groups of cells in 
one culture. Like any other technique, 
microinjection has certain limitations: As a 
single cell technique, microinjection is rarely 
used to transduce large number of cells and 
produce over-expressed proteins for in vitro 
experiments including detection and purification 
[11]. In addition, direct microinjection of 
proteins is most powerful to deliver cytosolic 
and nuclear proteins, but not membrane-located 
proteins, neurotransmitter receptors, or ion 
channels, although this transfer can be achieved 
by injecting the cDNAs of these membrane 
proteins. In dividing cell lines, the injected 
substances are constantly diluted by cell 
division; therefore, long incubation after 
injection of dividing cells is not recommended. 
Microinjection has been extensively used for 
primary cultured human neurons, since these 
cells are difficult to transfect. The researchers 
have successfully delivered proteins (e.g., 
recombinant caspases, Bax, Hsp70, neutralizing 




antibodies), peptides (e.g., β-amyloid), and 
various cDNA constructs into human neuronal 
cytosol [11]. 
 
Fig.1. Microinjection: Microinjection strategies utilize 
microneedles to deliver DNA directly to cell nuclei 
 
Photodynamic therapy  
     Photodynamic therapy (PDT) contains 
injection of a tumor photosensitizing agent, 
which may need metabolic synthesis of a 
prodrug, followed by activation of the agent 
using light in a specific wavelength. The 
preclinical and clinical studies have suggested 
photodynamic therapy as a useful treatment for 
some cancers [12-14]. The use of PDT on the 
CIN treatment has reported since 1990s as a 
non-destructive treatment [15]. This strategy has 
been applied to a variety of tissues that are 
accessible to light, including the retina, 
bronchial tree, skin, and the gastrointestinal tract 
[13-16]. Photodynamic therapy is another way to 
improve nucleic acid delivery to a specific light-
exposed site. In this process, amphiphilic 
photosensitizers co-localize with the nucleic acid 
in endocytic cellular vesicles and are 
subsequently activated by light, resulting in the 
destruction of endocytic membrane structures 
and releasing co-endocytosed nucleic acids into 
the cell cytosol [7]. The studies showed that 
PDT is a common method for treatment of skin 
cancer. For example, protoporphyrin IX, 
converted enzymatically from the prodrug 5-
aminolevulinic acid (ALA), is used as a 
photosensitizer in PDT for cancer. Enhancement 
of ALA penetration in skin can be achieved by 
other physical methods or addition of chemical 
penetration enhancers. Some researchers used 
lipophilic ALA derivatives to develop the 
transdermal delivery of ALA [17]. The use of 
nanoparticles such as metallic-, ceramic-, 
inorganic oxide-, and biodegradable polymer-
based nanomaterials, as carriers of 
photosensitizers, is a potent approach because 
they can improve all the requirements for an 
ideal PDT [18]. Photochemical internalization 
(PCI) strategy was also utilized to increase the 
release of endocytosed macromolecules to the 
cytosol. This method is based on the activation 
of endocytosed photosensitizers by light to 
stimulate the release of endocytic vesicle 
contents before they are transferred to the 
lysosome. The studies indicated that PCI 
facilitates endosomal escape of siRNA targeting 
EGFR [19].  
Jet injection 
     The jet injection method uses mechanical 
compression to force fluid (DNA in solution) 
through a small cavity, producing a high 
pressure flow that can penetrate in different 
tissues. Previously, a combination of plasmids 
encoding a marker gene and tumor necrosis 
factor gene (TNF-α) were jet-injected into 
subcutaneous Lewis lung carcinoma tumors. 
After five injections, high gene expression was 
observed within tumor tissues with a penetration 
depth of 5-10 mm, deeper than that in gene gun 
delivery [7, 20]. The capacity of various 
intradermal (id) DNA immunization delivered 
by needle or Biojector, with or without 
electroporation (EP) was studied to stimulate 
immune responses in mice model. The study 
showed that a high dose of DNA injected by 
needle plus EP or Biojector alone (100 μg) 
stimulated the levels of immune responses 
similar to those in lower dose of DNA (10 μg). 
The combination of Biojector-injection with EP 
showed significantly stronger immune responses 
after immunization with the high dose DNA as 
compared to the lower dose. Indeed, the 
combination of both methods could overcome 
dose limitations observed for DNA encoded 
antigens. In addition, the humoral responses 
were significantly enhanced by Biojector, while 
cellular responses were particularly increased by 
EP [21]. In general, Jet-injection has become an 
applicable technology among other non-viral 
delivery systems, such as electroporation or 
particle bombardment. This method delivers a 
drug or vaccine intradermally, subcutaneously, 
or intramuscularly via high pressure produced 
by either a carbon-dioxide-filled or nitrogen-
filled cartridge or a spring. Furthermore, the 




researchers showed that the repeated jet-
injections into one target tissue can be 
performed easily [22, 23]. Up to now, vaccines 
administered via jet injection could induce 
immune responses against typhoid, cholera, 
BCG, tetanus-diphtheria for adults, whole cell 
diphtheria-tetanus-pertussis (DTP), measles, 
meningococcal A and C, smallpox, yellow fever, 
hepatitis A, hepatitis B, influenza, plague, polio, 
and tetanus [24]. 
Ballistic DNA injection (particle bombardment) 
     This method of gene delivery was first 
developed for gene transfer into plants in 1987. 
After that, it has been modified to transfer genes 
into mammalian cells both in vitro and in vivo. 
The principle of this method is to transport 
DNA-coated gold particles against cells and 
force intracellular DNA transfer. The 
accelerating force for DNA containing particles 
can be a high-voltage electronic or helium 
pressure discharge. Ballistic DNA injection has 
been successfully used to transfer genes into 
various cell lines [8]. In vivo applications have 
extensively focused on the skin, muscle, liver or 
other organs that can be exposed after surgical 
procedure. Unfortunately, genes delivered by 
this method are expressed transiently, and there 
is considerable cell damage occurring at the 
centre of the discharge site. Among different 
methods, the gene gun-based delivery is more 
appropriate for gene delivery to skin due to the 
shallow penetration of DNA. This method has 
been used in vaccination against the influenza 
virus and in gene therapy for treatment of 
ovarian cancer [8]. 
Gene Gun 
     Particle bombardment through a gene gun is 
an effective and rapid tool to deliver exogenous 
materials into living tissue [25, 26]. DNA is 
deposited on the surface of gold (/ tungsten, or 
silver) particles, which are then accelerated by 
pressurized helium gas and expelled onto cells 
or a tissue [4]
 
(Figure.2). Recently, it has been 
known as a method of labeling neurons in a 
variety of preparations [25, 26]. This technology 
led to efficient in vitro transfection, even in the 
cells which are difficult to transfect [27]. 
Diolistics is ideal for loading cells with optical 
nano-sensors linked to fluorescent probes. 
Further development of nano-sensors, combined 
with the gene gun to deliver them, will enable 
the monitoring and quantification of an even 
greater range of cell metabolites in different 
cells [26]. Furthermore, this system is expected 
to have important applications as an effective 
tool for DNA-based vaccines. Further 
improvements including chemical modification 
of the surface of gold particles allow higher 
capacity and better stability for DNA coating, 
and also enhancement of the expelling force for 
exact control of DNA deposition into cells in 
various tissues [4]. Gas pressure, particle size, 
and the amount of the particles and DNA 
loading are critical factors that determine 
penetration efficiency to the tissues [27, 28]. The 
low pressure gene gun can deliver plasmid DNA 
at lower pressure [29]. Gene gun-based gene 
transfer has been broadly tested for 
intramuscular, intradermal and intratumor 
genetic immunization. It was demonstrated that 
this approach is able to produce more immune 
response with lower doses comparing to needle 
injection in large animal models and in clinical 
trials [28]. Furthermore, intradermal DNA 
vaccination via a gene gun represents one of the 
most efficient methods for delivering DNA 
directly into dendritic cells (DCs) [30]. When 
DNA vaccines are administered by gene gun, the 
majority of the plasmid is taken up by 
keratinocytes as well as antigen processing cells 
(APCs). It appears that DCs (Langerhans cells 
and bone marrow–derived DCs) transfected by 
gene gun play a key role in the stimulation of 
immunity. These transfected cells rapidly 
migrate to the draining lymph nodes where 
cross-presentation of antigen to CD8
+
 T cells 
occurs. These migratory transfected DCs alone 
are responsible for immunologic memory. The 
role of the non-migratory transfected 
keratinocytes expressing antigen is minimal 
[31]. However, some data showed that genetic 
immunization of the skin with gene gun is 
capable of eliciting immune responses 
independent of Langerhans cells (LCs) 
[32].Gene gun avoids several problems 
associated with other non-viral methods. The 
fact that DNA is delivered directly to the 
cytoplasm without going through the 
endocytosis pathway results in less degradation 
(i.e., cell receptor independent) [33, 34]. This 
also prevents the non-specific 
immunostimulatory effect observed with 




endocytosis dependent methods such as 
liposomes or polymers [34]. Comparing to other 
non-viral gene delivery methods, gene 
expression after particle bombardment is 
typically short term, but can be longer 
depending on the tissue (e.g., greater than 60 
days in muscle). This is not a limiting factor 
because gene gun are typically applied in 
situations where transient to near-term 
expression is necessary [34]. The use of this 
technology was reported to transfect tumors with 
granulocyte/macrophage-colony-stimulating 
factor (GM-CSF) plasmid DNA. This technique 
was simple to induce high levels of transgene 
expression [35]. A comparison of in vivo 
transfection efficiency by intramuscular 
injection and gene gun bombardment of plasmid 
DNA encoding EGFP gene revealed that the 
gene gun is more efficient in producing 
fluorescent fibres. In addition, administration of 
plasmid DNA showed that the gene gun 
generated high immune responses (~100-fold) 
compared to intramuscular injection per unit 
transfected DNA [36]. A major reason for the 
difference in efficiency between the two 
methods is likely a difference in the plasmid 
delivery mechanism. Intramuscular injection 
delivers the plasmid to the extracellular space 
and the plasmid may subsequently be taken up 
by cells using an unknown mechanism. It has 
been estimated that around 99% of the 
extracellularly delivered plasmid DNA is broken 
down by DNases and/or removed by liquid flow. 
In contrast, the gene gun technology delivers the 
plasmid DNA directly into the cytoplasm, thus 
bypassing the extracellular DNA degradation 
[36]. In the large animal model (e.g., pig), the 
combination of gene gun delivery and a plasmid 
DNA that targets APCs by expressing a CTLA4-
ovalbumin (OVA) fusion antigen, resulted in the 
enhancement of ovalbumin specific antibody 
responses [37]. Gene gun has the potential to be 
a safe and effective method of gene delivery; 
however, this technology has some significant 
drawbacks. Current designs of gene guns only 
penetrate superficially into the target tissue, 
limiting their use to dermal tissues. To overcome 
this limitation, a modified gene gun was 
developed to use higher pressures resulting in 
deeper penetration into the target tissue. This 
new gene gun was used to deliver a modified 
human papilloma virus [HPV] E7 gene as a 
tumor rejection antigen to mice. All of the 
treated animals developed protective immunity 
against HPV-positive tumors suggesting the 
potency of gene gun transfection in cells [34]. In 
vivo gene transfer into the beating heart is an 
attractive strategy for cardiovascular diseases 
[38, 39]. Gene gun-mediated transfer of the 
Epstein-Barr virus (EBV)-based episomal vector 
into rat heart resulted in long time gene 
expression [38]. RNA interference (RNAi) 
technology has developed into a powerful 
method for specific post-transcriptional gene 
silencing in vitro and may be applied to diminish 
the expression of immunosuppressive factors in 
vivo as a complement to traditional DNA 
vaccines. One approach leading to gene 
silencing is by transfection of DNA encoding 
short hairpin RNA (shRNA), targeting the gene 
of interest. The studies indicated that co-
administration of DNA encoding shRNA 
targeting luciferase significantly reduced 
luciferase expression in mice intradermally 
injected luciferase DNA [40]. Furthermore, mice 
vaccinated with E7-expressing DNA co-
administered with DNA encoding shRNA 
targeting FasL significantly enhanced the 
cellular immune responses as well as potent 
therapeutic antitumor effects against E7-
expressing tumors. Thus, intradermal 
administration of DNA encoding shRNA by 
gene gun represented a plausible approach to 
silence genes in vivo and a potentially useful 
tool to enhance DNA vaccine potency [40]. 
Gene gun bombardment has been used for 
successful mRNA transfection in several cell 
types and tissues. When mRNA encoding α-1 
antitrypsin was delivered in mice, a strong 
antibody response was observed, indicating the 
possibility of using this technique as a 
vaccination strategy. In addition, this approach 
was used to deliver mRNA encoding human 
epidermal growth factor (hEGF) suggesting 
increased wound healing. On the other hand, 
mRNA encoding GFP delivered by a gene gun 
resulted in expression up to one week as 
compared to 30 days when the plasmid DNA 
analogue was delivered [41]. For many years, it 
was generally accepted that mRNA is unstable 
to be efficiently used for gene therapy purposes. 
But, several research groups proved the 




feasibility of mRNA‐mediated transfection with 
appropriate efficiency and duration of protein 
expression, suggesting its major advantages over 
the use of plasmid DNA. For example, mRNA 
does not need to cross the nuclear barrier to 
exert its biological activity as well as the lack of 
CpG motifs, which reduces its immunogenicity 
[41]. Ballistic transfer with the gene gun can be 
used to transfer cDNA coated gold particles to 
the epithelium. The results indicated that the use 
of gene gun to transduce the endothelium was 
shown to severely damage [10]. In addition, 
gene gun immunization has been used for 
humans in a number of clinical trials (e.g., a 
malaria DNA vaccine) [32]. These trials 
reported that particle-mediated DNA 
immunization of humans is safe, well tolerated 
and results in strong immune responses to the 
plasmid-encoded antigens. In the case of 
hepatitis DNA vaccines, gene gun immunization 
not only induced protective levels of antibody, 
but also immunized individuals who had not 
responses to the recombinant protein vaccine 
(licensed vaccine) [42]. 
Electroporation 
     The use of an electric field to alter the cell 
permeability was known since 1960s. However, 
the first in vitro and in vivo attempts to use 
electroporation (EP) in gene transfer were 
demonstrated in 1982 and 1991, respectively 
[28].  
 
Fig.2. Ballistic gene delivery (Gene gun): Plasmid 
DNA is mixed with gold or tungsten particles ranging 
in size from nanometers to microns 
Electroporation is a method that uses short 
pulses with high voltage to carry DNA across 
the cell membrane. This shock is thought to 
cause temporary formation of pores in the cell 
membrane, allowing DNA molecules to pass 
through [43, 44]. Electroporation is generally 
efficient and works across a broad range of cell 
types. However, a high rate of cell death 
following electroporation has limited its use, 
including clinical applications [10]. 
Electroporation method employs high field 
strength, square-wave electric pulses to allow 
the penetration of therapeutics molecules across 
cell membrane (Figure.3). While this method 
does not involve any biochemical agents and is 
thus considered a safe choice, electroporation 
can cause severe cell damage and induce 
immunogenic reactions. Electroporation was 
successfully used to deliver IL-10 gene to mice 
corneas. In vivo gene transfer to the endothelium 
and stromal keratocytes has been reported in 
rats. However, high voltage (> 500V) can be 
hazardous [10]. Electroporation can induce long-
lasting gene expression and can be used in 
various tissues [2]. However, it is necessary to 
optimize factors such as dose of DNA, electrode 
shape and number, electrical field strength and 
duration. The optimized conditions were applied 
for expression of hepatitis B surface antigen, 
erythropoietin and IL-12 in cells. For example, 
potent immune responses against hepatitis B 
surface antigen and HIV gag protein were 
obtained by electroporation of muscle after 
intramuscular injection of plasmid DNA. 
Comparing with local injection of DNA to the 
liver, systemic injection has the advantage of 
delivering genes more equally to the liver [2]. 
The in vivo electroporation was evaluated for the 
enhancement of immune responses induced by 
DNA plasmids encoding the pre-erythrocytic 
Plasmodium yoelii antigens PyCSP and 
PyHEP17 administered intramuscularly and 
intradermally to mice. Immunization with 5 μg 
of DNA via EP was equivalent to 50 μg of DNA 
via conventional needle, thus reducing by 10-
fold the required dose to produce the same 
immune effects [45]. Electroporation has been 
successfully used to administer HPV DNA 
vaccine to mice as well as rhesus macaques, 
which has prompted its use in an ongoing phase 
I clinical trial such as VGX-3100, a vaccine that 
includes plasmids targeting E6 and E7 proteins 
of both HPV subtypes 16 and 18, for treatment 




of patients with CIN 2 or 3. In addition, 
electroporation has been used as an effective 
vaccination technique for the treatment of HPV 
induced cancers using the pNGVL4a-CRT/E7 
(detox) DNA vaccine [46]. It was shown that 
subcutaneous administration of HPV16 E7 DNA 
linked to C-terminal fragment of gp96 followed 
by electroporation can significantly enhance the 
potency of DNA-based vaccines [47-50]. 
Electroporation is a versatile method that 
has been broadly examined in many types of 
tissues in vivo. The level of reporter gene 
expression was 2 to 3 times higher than that 
with plasmid DNA alone. Long-term 
expression over one year was observed after 
a single electroporation treatment. The 
amount of DNA and how well the injected 
plasmid DNA distributes within the treated 
tissue prior to electroporation appear to have 
an important effect on transfection efficacy 
[4]. It was also reported that age of the 
recipient animals affects the transfection 
efficiency in mice. Treatment of muscle 
with hyaluronidase prior to injection of 
plasmid DNA to relax the surrounding 
extracellular matrix significantly enhanced 
transfection, likely due to improved 
distribution of plasmid DNA in the tissue. 
Alternatively, plasmid DNA administration 
through the portal vein followed by 
localized electroporation on rat liver resulted 
in widespread transfection in hepatocytes in 
the treated lobe but not in the surrounding 
lobes. This result suggests the possibility 
that cells can be transferred with plasmid 
DNA via blood circulation and then 
electroporation is used to a selected area to 
achieve localized gene transfer. A short time 
interval between DNA injection and 
electroporation is critical to minimize DNA 
degradation by extracellular nucleases [4, 
28]. Several major drawbacks exist for in 
vivo use of electroporation including a) it 
has a limited effective range of ~1 cm 
between the electrodes, which makes it 
difficult to transfect cells in a large area of 
tissues; b) a surgical procedure is required to 
place the electrodes deep into the internal 
organs; c) high voltage used to tissues can 
result in irreversible tissue damage as a 
result of thermal heating. Ca 
2+
 influx due to 
disruption of cell membranes may induce 
tissue damage because of Ca 
2+
-mediated 
protease activation. The possibility that the 
high voltage applied to cells could affect the 
stability of genomic DNA, is an additional 
safety concern. However, some of these 
concerns may be solved by optimizing the 
design of electrodes, their spatial 
arrangement, the field strength, and the 
duration and frequency of electric pulses [4]. 
In vivo electroporation technique is 
generally safe, efficient, and can produce 
good reproducibility compared to other non-
viral delivery systems. When parameters are 
optimized, this method can generate 
transfection efficiency equal to that achieved 
by viral vectors [28].Electroporation 
efficiently works on cells that are suspended 
in solution, but also works on cells in solid 
tissue where electrodes can be applied [8, 
41]. In vivo electroporation induces a low 
level of inflammation at the injection site, 
facilitating DNA uptake by parenchyma 
cells and antigen-presenting cells [8]. Up to 
now, several clinical trials have been 
planned using the electroporation with DNA 
vaccines for cancer therapy such as: a) Intra-
tumoral IL-12 DNA plasmid (pDNA) [ID: 
NCT00323206, phase I clinical trials in 
patients with malignant melanoma, [51, 52]; 
b) Intratumoral VCL-IM01 (encoding IL-2) 
[ID: NCT00223899; phase I clinical trials in 
patients with metastatic melanoma]; c) 
Xenogeneic tyrosinase DNA vaccine [ID: 
NCT00471133, phase I clinical trials in 
patients with melanoma]; d) VGX-3100 [ID: 
NCT00685412, phase I clinical trials for 
HPV infections], and e) IM injection 
prostate-specific membrane antigen 
(PSMA)/ pDOM fusion gene [ID: UK-112, 
phase I/II clinical trials for prostate cancer 
[44, 53-56]. The limitation of the current 




procedure is that the number of cells 
transfected is relatively small and that 
surgery is required to reach internal organs 
[8]. Recent patents have been focused on the 
use of genetic immunomodulators, such as 
T- helper epitopes derived from tetanus 
toxin, E. coli heat labile enterotoxin and 
vegetable proteins, as well as cytokines, 
chemokines or co-stimulatory molecules 
such as IL-6, IL-15, IL-21 to increase 
immune responses against cancer. 
Electroporation-based DNA delivery 
technology could efficiently enhance 
cellular uptake of these DNA vaccines [57]. 
Electroporation with mRNA has been 
performed in dendritic cells, because of their 
possible use in vaccination strategies. 
Loading DCs with mRNA encoding 
different tumor associated antigens (TAAs) 
proved to be efficient, transfecting up to 50-
75% of treated cells. Electroporation of DCs 
with mRNA is a safe and relatively easy 
method. It has already been tested in clinical 
trials (e.g. transfection of mRNA encoding 
prostate specific antigen (PSA)) [41]. 
Altogether, this technology has been 
successfully used to enhance the skin 
permeability of molecules with differing 
lipophilicity and size (i.e., small molecules, 
proteins, peptides and oligonucleotides) 
including biopharmaceuticals with 
molecular weights greater than 7 kDa [58]. 
Drug delivery by electroporation has been 
used for cancer treatment since 1991 as 
shown in eleven studies of 
electrochemotherapy (ECT) of malignant 
cutaneous or subcutaneous lesions, e.g., 
metastases from melanoma, breast or head- 
and neck cancer. The treatments were well 
tolerated in patients [59].  
Ultrasound 
     This system can directly deliver plasmid 
DNA and siRNA into cytosol without 
endocytosis pathway. Therefore, these genes are 
able to escape from degradation in lysosome and 
result in enhancing the efficiency of gene 
expression. 
 
Fig.3. Electroporation: Electroporation strategies use 
a current across cells or tissues to make cell 
membranes more permeable to exogenous DNA 
In addition, it is expected that ultrasound-
mediated gene delivery using 
nano/microbubbles would be a system to 
establish non-invasive and tissue specific gene 
expression because ultrasound can transdermally 
expose to target tissues and organs [60]. 
Ultrasound can increase the permeability of cell 
membrane to macromolecules such as plasmid 
DNA (Figure.4). Indeed, enhancement of gene 
expression was observed by irradiating 
ultrasonic wave to the tissue after injection of 
DNA. Since the use of ultrasound is flexible and 
safe, its use in gene delivery has a great 
advantage in clinical use. Recently, it was 
reported that combination of microbubble with 
ultrasound could further increase the gene 
expression level. Microbubbles, or ultrasound 
contrast agents, decrease the threshold for 
cavitation by ultrasound energy. In most cases, 
perfluoropropane filled albumin microbubbles or 
Optison were used as microbubbles. It was 
modified with plasmid DNA before injection, 
followed by irradiation of ultrasound. At 
present, this technique is used for gene delivery 
to vascular cells, muscle and fetal mouse [2, 61]. 
The transfection efficiency of this system is 
determined by several factors, including the 
frequency, the output strength of the ultrasound, 
the duration of ultrasound treatment, and the 
amount of plasmid DNA. The efficiency can be 
enhanced by conditions that make membranes 
more fluidic. Unlike electroporation, which 
moves DNA along the electric field, ultrasound 
creates membrane pores and facilitates 




intracellular gene transfer through passive 
diffusion of DNA across the membrane pores. 
Consequently, the size and local concentration 
of plasmid DNA play an important role in 
determining the transfection efficiency. Efforts 
to reduce DNA size for gene transfer through 
proper formulation could result in further 
improvement. Interestingly, significant 
enhancement has been reported in vitro and in 
vivo when complexes of DNA and cationic 
lipids have been used. So far, the major problem 
for ultrasound-facilitated gene delivery is low 
gene delivery efficiency [4]. The effects of 
ultrasound not only enhanced the vaccine 
delivery but also stimulated activation of APCs 
in the epidermis of animals [43]. The results 
suggested that high-intensity ultrasound could be 
useful for the treatment of small cancerous 
tumors such as low-grade prostate carcinoma 
[62]. The researchers indicated that 
complexation with the PEG-introduced 
cationized dextran combined with US irradiation 
is a promising way to target the plasmid DNA to 
the tumor for gene expression. Fluorescent 
microscopic studies revealed that the 
localization of plasmid DNA and the gene 
expression were observed in the tumor tissue 
injected with the PEG introduced cationized 
dextran-plasmid DNA complex plus the 
subsequent US irradiation [63].The use of 
ultrasound for the delivery of drugs through the 
skin is commonly known as sonophoresis or 
phonophoresis [64]. The first indication that 
ultrasound might enhance the transdermal 
penetration of drugs was demonstrated in 1954. 
Sonoporation, is a technique that uses ultrasound 
waves to create plasma membrane defects by 
acoustic cavitation. With each ultrasonic cycle, a 
fraction of the energy of the propagating wave is 
absorbed by the tissue resulting in local heating 
which affects the structure of cell membranes. 
Tissue absorption to ultrasound waves depends 
on tissue type and ultrasound frequency and 
intensity. A major improvement in ultrasound-
based gene transfer was the combination of 
ultrasound irradiation with microbubbles. The 
size of microbubbles (~ 1-6 μm), is important 
for the efficient transfection and for not being 
eliminated by the reticular endothelial system 
(RES) [28]. Modification of microbubbles 
through lipid or polymer coating resulted in 
enhanced transfection efficiency. However, 
enhancement of fluidity of the cell membrane by 
feeding cells with long-chain unsaturated fatty 
acids, which facilitates its flexibility and 
minimizes cellular resistance to sonication, was 
also suggested to improve the effect of 
sonoporation. The major advantage for 
sonoporation is its safety, noninvasiveness, and 
being able to reach internal organs without 
surgical procedure. Recently, ultrasound has 
been shown to enhance the permeability of 
blood-brain barrier. Interestingly, targeted gene 
delivery can be achieved through sonoporation 
using non-targeted microbubbles or through 
microbubbles equipped with site specific 
ligands, such as antibodies or biotin–streptavidin 
that helps in transferring of microbubbles to 
certain tissue or organ [28]. Sonoporation 
mediated gene delivery has been demonstrated 
in the cornea, brain, CNS, bone, peritoneal 
cavity, kidney, pancreas, liver, embryonic tissue, 
dental pulp, muscle and heart. More recent 
studies in mouse liver showed that inclusion of 
gas-filled microbubbles enhanced gene delivery 
efficiency. Similar results were also obtained in 
tumor, vascular tissue and skeletal muscles [8]. 
A combination of ultrasound therapy with 
topical drug therapy was done to achieve 
therapeutic drug concentrations at selected sites 
in the skin. In this technique, the drug was 
mixed with a coupling agent usually a gel but 
sometimes a cream or ointment was used which 
transfers ultrasonic energy from the device to the 
skin through this coupling agent. Application of 
low frequency ultrasound (20-100 KHZ) 
enhances skin permeability more effectively 
than high-frequency ultrasound (1-16 MHZ). 
The mechanism of transdermal skin permeation 
involved disruption of the stratum corneum 
lipids, thus allowing the drug to pass through the 
skin. A corresponding reduction in skin 
resistance was observed due to cavitation, 
microstreaming and heat generation [58]. 
Generally, ultrasound is very effective in 
permeabilizing the skin especially at low 
frequencies. This strategy has been shown to 
enhance the delivery of vaccines into skin. The 
studies indicated that the immune response 
generated by ultrasonically delivered vaccine 
was about 10-fold higher than that in SC 
injection per unit dose of the vaccine [24]. 





Fig.4. Sonoporation: Ultrasonic frequencies are used to 
induce the cavitation of microbubbles for creating pores in 
cells, which allows cells to be temporarily more permeable 
to plasmid DNA 
Hydrodynamic injection (Hydroporation) 
     Hydrodynamic injection, a rapid injection of 
a large volume of naked DNA solution (5 mg 
plasmid DNA injected in 5-8 s in 1.6 ml saline 
solution for a 20 g mouse) via the tail vein, can 
induce potent gene transfer in internal organs, 
especially the liver. The naked plasmid DNA is 
taken up by receptor-mediated pathway in 
hepatocytes [2]. Certain DNA receptors have 
been found in various tissues; however, their 
function has not been elucidated. It has been 
proposed that the injected DNA solution 
accumulates mainly in the liver because of its 
flexible structure which can accommodate large 
volume of solution, and the hydrostatic pressure 
drives DNA into the liver cells before it is mixed 
with blood. Furthermore, breaking of the 
endothelial barrier by the pressure has been 
proposed as the major mechanism responsible 
for the highly efficient expression in the liver 
[2]. Hydrodynamics-based transfection (HBT) of 
hepatocytes has been reported to produce 
suitable transfection efficiency in mice 
65
. 
Hydrodynamic gene delivery is a simple method 
that introduces naked plasmid DNA into cells in 
highly perfused internal organs with an 
impressive efficiency. The gene delivery 
efficiency is determined by the anatomic 
structure of the organ, the injection volume, and 
the speed of injection. Electron microscopy 
shows the existence of transient membrane 
defects in hepatocytes shortly after the 
hydrodynamic treatment, which could be the 
mechanism for plasmid DNA to enter the 
hepatocytes. Approximately 30- 40% of the 
hepatocytes are transfected by a single 
hydrodynamic injection of less than 50 μg of 
plasmid DNA. Various substances of different 
molecular weight and chemical structure 
including small dye molecules, proteins, 
oligonucleotides, small interfering RNA, and 
linear or circular DNA fragments as large as 175 
kb have been delivered by this method. The non-
specific nature of hydrodynamic delivery 
suggests that this method can be applied to 
intracellular delivery of any water-soluble 
compounds, small colloidal particles, or viral 
particles. Hydrodynamic delivery allows direct 
transfer of substances into cytoplasm without 
endocytosis [4]. This method has been used to 
express proteins of therapeutic value such as 
hemophilia factors, α-1 antitrypsin, cytokines, 
hepatic growth factors and erythropoietin in 
mouse and rat models. Depending on the 
plasmid construct and the regulatory elements 
driving expression of the transgene, the level of 
gene expression in some cases has exceeded the 
physiological level. The fact that a bacterial 
artificial chromosome containing an entire 
chromosomal transcription unit and replication 
origin (>150 kb) can be delivered successfully to 
the liver using this method, opens up many 
applications for gene therapy in liver-associated 
genetic diseases [4]. The real challenge for gene 
transfer by the hydrodynamic method is how to 
translate this simple and effective procedure to 
one that is applicable to humans. Rat liver can 
be transfected similarly through tail vein 
injection using an injection volume equivalent to 
8-9% of body weight. If the same ratio is 
extrapolated to humans, one would have to 
inject up to 7.5 L of saline at a high rate, which 
is obviously many times over the maximal 
volume that a person can tolerate. However, 
successful liver transfection has been achieved 
using balloon catheter-based and occlusion-
assisted infusion to specific lobes in rabbit and 
swine models, indicating that with modification, 
hydrodynamic gene delivery can become a 
clinically relevant procedure [4]. Hydrodynamic 
i.v. injection involves the rapid i.v. injection of 
siRNA in large volumes of physiological buffer 
to achieve effective localization of duplex 
siRNA mainly in the liver, although distribution 
to the kidney, lung, and pancreas has been 
reported. Effective gene silencing in the liver of 




mice has been demonstrated using this delivery 
strategy with both unmodified and chemically 
modified siRNAs. Although the exact 
mechanisms of how siRNA is delivered to cells 
by hydrodynamic injection are unclear, it is 
possible that the high pressure causes membrane 
perturbations that facilitate siRNA uptake in 
vivo by some cell types, even though they all 
might show membrane disruption. However, this 
delivery method cannot be directly translated to 
clinical use due to both the large injection 
volumes and the cellular toxicities caused by the 
high pressure of the injection [66]. 
Laser-Assisted Method (Photoporation) 
    The photoporation method employs a single 
laser pulse as the physical force to generate 
transient pores on a cell membrane to allow 
DNA to enter. Gene delivery efficiency appears 
to be controlled by the size of the focal point and 
pulse frequency of the laser (Figure.5). The level 
of transgene expression was similar to that of 
electroporation. In recent years, several 
advances have been made to improve gene 
delivery efficiency, one of which involved the 
use of carbon black nanoparticles to generate 
photoacoustic force upon laser stimulation 
8
. 
Applications of the femtosecond laser are 
becoming more accepted in corneal refractive 
surgery and transplantation, due to high 
precision and safety, compared to conventional 
laser. The femtosecond laser can be used to 
create a pocket where in the corneal surface to 
assist the delivery of therapeutic agents. It was 
used to deliver the vector to the stroma, 
therefore it is suggested to be used in chronic 
stromal herpetic keratitis conditions, if the 
latency of HSV-1 is in the stroma [10]. 
Magnetofection 
Magnetofection uses a magnetic field to promote 
transfection. This method employs magnetic 
nanoparticles made of iron oxide and coated 
with cationic lipids or polymers to complex with 
DNA through electrostatic interaction. The 
magnetic particles are then concentrated on the 
target cells by the influence of an external 
magnetic field. Similar to the mechanism of 
non-viral vector-based gene delivery, the 
cellular uptake of DNA is accomplished by 
endocytosis and pinocytosis. 
 
 
Fig.5. Laser Induced Pore Formation: Pulsed lasers 
have been shown to perforate cell membranes similar 
to microinjection strategies, but without the use of a 
needle. 
 
It is postulated that DNA are released into the 
cytoplasm depending on the composition of the 
magnetic nanoparticles. Magnetofection has 
been successfully applied to a wide range of 
primary cells and cells that are hard to transfect 
using other non-viral methods. Recent work 
using a local injection of the nanoparticles into 
the gastrointestinal track and the ear vasculature 
involve that this method for in vitro gene 
delivery may be applicable to in vivo gene 
delivery [8, 43]. More importantly, the high 
transduction efficiency observed in vitro was 
reproduced in vivo with magnetic field-guided 
local transfection in the gastrointestinal tract and 
in blood vessels. Magnetic targeting uses 
paramagnetic particles as drug carriers, conducts 
their accumulation in target tissues with local 
strong magnetic fields, and has been used with 
some success in the treatment of cancer patients 
[67]. Magnetic forces have been previously used 
to enhance delivery of anticancer drugs to 
tumors, as well as in the context of gene therapy. 
More recently, magnetofection has been used to 
transfect primary airway cells in vitro, as well as 
airway epithelium from porcine trachea, ex vivo. 
The proposed mechanism for magnetofection is 
an increase in the concentration of the vector on 
the cell surface, thereby increasing the contact 
time and subsequently gene transfer [68]. 
Tattooing 
     Tattooing is one of a number of DNA 
delivery methods which results in an efficient 




gene expression in the epidermal and dermal 
layers of the skin. The tattoo procedure causes 
many minor mechanical injuries followed by 
hemorrhage, necrosis, inflammation and 
regeneration of the skin and thus non-
specifically stimulates the immune system. DNA 
vaccines delivered by tattooing have been shown 
to induce higher specific humoral and cellular 
immune responses than intramuscularly injected 
DNA [69]. In a study, the comparison of HPV 
16 L1 DNA immunization protocols using 
different routes of DNA injection (intradermal 
tattoo versus intramuscular injection) and 
molecular adjuvants (cardiotoxin pre-treatment 
or GM-CSF DNA codelivery) was done. 
Cardiotoxin pretreatment or GM-CSF DNA co-
delivery substantially enhanced the efficacy of 
DNA vaccine delivered intramuscularly by 
needle injection but had virtually no effect on 
the tattoo vaccination. The promoting effect of 
both adjuvants was more prominent after three 
rather than four immunizations. Tattooing 
elicited significantly higher L1-specific humoral 
and cellular immune responses than 
intramuscularly delivered DNA in combination 
with adjuvants. Indeed, the route of DNA 
delivery had a higher effect on the vaccination 
efficiency than the use of adjuvants (e.g., GM-
CSF and cardiotoxin) [69].The mechanisms 
involving DNA tattooing to generate better 
immune response include: a) better uptake of the 
DNA by non-antigen-presenting cells, b) better 
uptake of DNA by antigen-presenting cells, c) 
duration of expression or d) the induced 
traumata by the tattooing. The advantage of 
tattoo treatment is the low price of the tattoo 
device and a standardized method for the use. In 
particular, the local traumata induced by 
tattooing might not be considered acceptable in 
prophylactic vaccination; but, However, DNA 
vaccination via tattoo seems to be suitable if 
faster and stronger immune responses have to be 
achieved [69]. In a study, for determination of 
the effect of the tattooing process on DNA 
vaccine stability, the change of DNA topology 
was evaluated such as critical factors for antigen 
expression and immune response. It was found 
that the DNA tattooing had minor effect on 
DNA structure and activity. In addition, an 
adenoviral vector-based vaccine against 
respiratory syncytial virus, and a peptide vaccine 
against human papillomavirus were 
administrated by ID tattooing. In the case of the 
adenoviral vector vaccine, tattooing showed 
similar results to ID injection. Tattooing of the 
peptide vaccine with CpG motifs as an adjuvant 
showed better response than IM vaccination 
with adjuvant [24]. 
Transdermal drug delivery system (TDDS) 
     Transdermal drug delivery system is a novel 
drug delivery system and its aim to achieve a 
programmed delivery of the therapeutic products 
when applied on the skin for the optimal 
beneficial effects while avoiding the side effects 
of drugs [70, 71]. Drug selection criteria for 
transdermal patch contain: a) The dose of drug 
should be low i.e. < 20 mg/day; b) The drug 
should have short half life; c) The drug should 
have Molecular weight < 400 Daltons (high 
molecular weight fail to penetrate the stratum 
corneum); d) The drug should have partition 
coefficient between 1.0 and 4; e) Drug should be 
non-irritating and non- sensitizing to the skin; f) 
The drug should have low oral bioavailability; g) 
The drug should have low therapeutic index; j) 
The drug should have affinity for both lipophilic 
and hydrophilic phases, and k)The drug should 
have low melting point (less than 200°C) [72]. 
The effective transdermal drug delivery can be 
formulated by considering three factors as drug, 
skin, and the vehicles. So the factors affecting 
can be divided into classes as biological factors 
and physicochemical factors. Biological factors 
include skin condition, skin age, blood supply, 
regional skin site, skin metabolism and species 
differences. Physicochemical factors include 
skin hydration, temperature and pH, diffusion 
coefficient, drug concentration, partition 
coefficient, and molecular size and shape. 
Electrically-based enhancement techniques have 
already been studied for drug delivery such as a) 
Iontophoresis: In iontophoretic delivery devices, 
drug is placed on the skin under the active 
electrode, and a current (< 0.5mA) passed 
between the two electrodes effectively repelling 
drug away from the active electrode and into the 
skin; b) Ultrasound: The use of ultrasound with 
a suitable frequency significantly enhances the 
transdermal transport of drugs through skin 
system (phonophoresis or sonophoresis). It is a 
combination of ultrasound therapy with topical 
drug therapy to achieve therapeutic drug 




concentrations at selected sites in the skin [72]; 
c) Photomechanical waves: The mechanism of 
photochemical wave was found to act by 
producing changes in the lacunar system which 
results in the formation of transient channels 
through the stratum corneum by 
permeabilization mechanism; d) Electroporation: 
In this method, aqueous pores are generated in 
the lipid bilayers by the use of short electrical 
pulses of approx 100-1000 volt/cm. It may 
combine with Iontophoresis to enhance the 
permeation of peptide; e) Electro-osmosis: If a 
charged porous membrane is subjected to a 
voltage difference, a bulk fluid or volume flow, 
called electro-osmosis [70].  
CONCLUSION 
     Although, various viral and non-viral delivery 
systems have been improved in the recent years, 
all of them have limitations in their clinical 
application; however, some delivery systems have 
been determined which can be efficient for gene 
delivery to specific cells or tissues. It seems that 
more efforts are needed for developing successful 
delivery systems. Altogether, key points in 
improving the current systems include: a) 
improving extracellular targeting and delivery, b) 
increasing intracellular delivery and long-time 
expression, and c) reducing toxicity and side 
effects on human body. So far, different non-viral 
approaches have been proposed for efficient drug 
and gene delivery, such as physical techniques and 
chemical methods. Physical delivery systems are 
one of the efficient non-viral methods including 
electroporation, micro-injection, gene gun, 
tattooing, laser and ultrasound. Physical methods 
of gene (and/or drug) transfer, need to combine 
two effects to deliver the therapeutic material into 
cells. The    physical   methods   must     induce  
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reversible alterations in the plasma membrane to 
allow the direct transfer of the molecules of 
interest into the cell cytosol. They must also 
bring the nucleic acids in contact with the 
permeabilized plasma membrane or facilitate 
access to the inside of the cell. These two effects 
can be achieved in one or more steps, depending 
on the methods used. Regarding to previous 
studies, among different physical approaches, 
electroporation and then gene gun has been used 
into clinical therapies, such as deliver drugs to 
tumors. Delivery of DNA vaccines using 
physical delivery systems especially 
electroporation has already been tested 
successfully in a wide range of disease models. 
Electroporation has been used to enhance 
immune responses using DNA vaccines directed 
against infectious diseases such as influenza, 
HIV, hepatitis C, malaria, anthrax or to treat or 
prevent the development of tumors including 
breast cancer, prostate cancer and melanoma. 
However, all these systems need to be optimized 
to reduce the main side effects for clinical trials
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